These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10658570)

  • 21. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
    Balzarini J
    Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure.
    Briones C; Soriano V; González-Lahoz J
    AIDS; 2000 Jul; 14(11):1659-60. PubMed ID: 10983655
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of nonnucleoside HIV reverse transcriptase inhibitors.
    Tucker TJ; Lumma WC; Culberson JC
    Methods Enzymol; 1996; 275():440-72. PubMed ID: 9026654
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA notifications. Generic abacavir and lamivudine combo approved.
    AIDS Alert; 2008 Oct; 23(10):115. PubMed ID: 18935685
    [No Abstract]   [Full Text] [Related]  

  • 27. Asymmetric synthesis of 4'-alpha-alkylcarbovir derivatives.
    Kato K; Suzuki H; Tanaka H; Miyasaka T
    Nucleic Acids Symp Ser; 1997; (37):61-2. PubMed ID: 9585999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir gets green light from FDA advisory board. Food and Drug Administration.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of 5-alkynylated d4T analogues as potential HIV-1 reverse transcriptase inhibitors.
    Ciurea A; Fossey C; Gavriliu D; Delbederi Z; Sugeac E; Laduree D; Schmidt S; Laumond G; Aubertin AM
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):511-9. PubMed ID: 15662955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Product information.
    Bartlett JG
    Hopkins HIV Rep; 1999 Mar; 11(2):6-7. PubMed ID: 11366250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abacavir warning.
    AIDS Patient Care STDS; 2000 Nov; 14(11):617. PubMed ID: 11155904
    [No Abstract]   [Full Text] [Related]  

  • 34. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 Jun; 24(6):396-7. PubMed ID: 20572321
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.
    AIDS Alert; 2009 Feb; 24(2):22. PubMed ID: 19219952
    [No Abstract]   [Full Text] [Related]  

  • 36. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
    AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 38. Alovudine Medivir.
    Rusconi S
    Curr Opin Investig Drugs; 2003 Feb; 4(2):219-23. PubMed ID: 12669386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity.
    Palomba M; Rossi L; Sancineto L; Tramontano E; Corona A; Bagnoli L; Santi C; Pannecouque C; Tabarrini O; Marini F
    Org Biomol Chem; 2016 Feb; 14(6):2015-24. PubMed ID: 26754878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and anti-HIV activity of L-2',3'-Dideoxy-4'-selenonucleosides (L-4'-Se-ddNs).
    Yu J; Kim G; Jarhad DB; Kim HR; Jeong LS
    Arch Pharm Res; 2019 Sep; 42(9):780-789. PubMed ID: 31041687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.